WGS Earnings Date: Nov 9, 2026 (Estimated) — GeneDx Holdings Corp.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is WGS's next earnings date?
GeneDx Holdings Corp. (WGS) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.07 on revenue of $122.9M.
How did WGS do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), GeneDx Holdings Corp. posted EPS of $0.01 versus the -$0.19 estimate, a beat of 105.3%. Revenue was $114.4M against a $110.7M estimate. The stock's 1-day post-earnings move was +4.5%.
How much does WGS stock move after earnings?
WGS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 26.7% (up or down) in the day after earnings.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
🤖 AI Earnings Analysis
WGS’s long-read sequencing expansion strengthens its rare-disease diagnostics position, but a -4.92% profit margin and -15.4 P/E underscore continued losses.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -0.19 | 0.01 | +105.26% | $114.4M | ✅ Beat | +4.48% | +14.77% | +24.98% |
| 2026-05-04 | Q1 2026 | -0.03 | -0.28 | -833.33% | $102.3M | ❌ Miss | -49.20% | -41.69% | -21.95% |
| 2026-02-23 | Q4 2025 | 0.12 | 0.14 | +16.67% | $121.0M | ✅ Beat | +6.12% | -2.86% | -12.09% |
| 2025-10-28 | Q3 2025 | 0.37 | 0.49 | +32.43% | $116.7M | ✅ Beat | +5.21% | +5.85% | +28.21% |
| 2025-07-29 | Q2 2025 | 0.10 | 0.50 | +400.00% | $102.7M | ✅ Beat | +8.09% | +27.61% | +48.69% |
| 2025-04-30 | Q1 2025 | 0.09 | 0.27 | +200.00% | $87.1M | ✅ Beat | -42.85% | -45.91% | -40.17% |
| 2025-02-18 | Q4 2024 | 0.10 | 0.60 | +500.00% | $95.6M | ✅ Beat | +47.69% | +24.43% | +18.91% |
| 2024-10-29 | Q3 2024 | -0.21 | 0.04 | +119.05% | $76.9M | ✅ Beat | +49.88% | +34.07% | +43.63% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $226.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Diagnostic Test | 49.4% | $111.9M | +12.1% | $155.3M | $85.8M | $99.8M | $113.5M |
| Diagnostic Test, Third Party Insurance | 41.9% | $94.7M | +16.8% | $123.1M | $68.1M | $81.1M | $95.0M |
| Diagnostic Test, Institutional Customers | 7.1% | $16.1M | -12.3% | $31.0M | $17.6M | $18.4M | $17.9M |
| Product and Service, Other | 1.1% | $2.6M | -11.0% | $2.8M | $1.4M | $2.9M | $3.2M |
| Diagnostic Test, Self Pay | 0.5% | $1.0M | +207.4% | $1.2M | $96K | $339K | $629K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.